Frazier Life Sciences funds (NASDAQ: KALV) disclose updated KalVista ownership

Rhea-AI Filing Summary

KalVista Pharmaceuticals received an Amendment No. 8 to a Schedule 13D from a group of Frazier Life Sciences funds and related entities updating their ownership information. Frazier Life Sciences Public Fund, L.P. directly holds 1,249,165 shares of KalVista common stock, representing 2.3% of the outstanding shares based on 53,240,888 shares outstanding as of May 7, 2026. Frazier Life Sciences X, L.P. holds 427,983 shares (0.8%), Frazier Life Sciences XI, L.P. holds 145,592 shares (0.3%), and Frazier Life Sciences XII, L.P. holds 6,563 shares (0.0%). The filing clarifies that certain entities act as general partners to these funds and that James N. Topper and Patrick J. Heron share voting and investment power only over the FLS X shares, with other funds managed by investment committees where individual members are not attributed beneficial ownership.

Key Figures

FLSPF KalVista stake: 1,249,165 shares FLSPF ownership percentage: 2.3% FLS X KalVista stake: 427,983 shares +5 more

8 metrics

FLSPF KalVista stake 1,249,165 shares Directly held by Frazier Life Sciences Public Fund, L.P.

FLSPF ownership percentage 2.3% Based on 53,240,888 shares outstanding as of May 7, 2026

FLS X KalVista stake 427,983 shares Directly held by Frazier Life Sciences X, L.P.

FLS X ownership percentage 0.8% Based on 53,240,888 shares outstanding as of May 7, 2026

FLS XI KalVista stake 145,592 shares Directly held by Frazier Life Sciences XI, L.P.

FLS XI ownership percentage 0.3% Based on 53,240,888 shares outstanding as of May 7, 2026

FLS XII KalVista stake 6,563 shares Directly held by Frazier Life Sciences XII, L.P.

Shares outstanding 53,240,888 shares KalVista common stock outstanding as of May 7, 2026

Key Terms

Schedule 13D, beneficial ownership, venture capital fund, general partner, +2 more

6 terms

Schedule 13D regulatory

"This Amendment No. 8 to a Schedule 13D amends the statement"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

beneficial ownership financial

"no members of such committee are attributed beneficial ownership of the securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

venture capital fund financial

"FLSPF is a venture capital fund concentrating in life sciences"

general partner financial

"The sole business of FHMLSP, L.P. is to serve as general partner of FLSPF"

A general partner is the person or firm that runs an investment partnership and legally represents it — they make the day-to-day decisions, choose which assets to buy or sell, and are responsible for the partnership’s obligations. Investors care because the general partner’s judgment, risk-taking and fee and profit-sharing arrangements determine both the potential returns and the level of exposure to losses; think of the GP as the ship’s captain whose skill and honesty shape the voyage’s outcome.

working capital financial

"The working capital of FLSPF, FLS X, FLS XI and FLS XII was the source of the funds"

Working capital is the money a business has available to cover its daily expenses, like paying bills and buying supplies. It’s like the cash in your wallet that helps you handle everyday costs; having enough ensures the business can operate smoothly without running into money shortages.

investment committee financial

"FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote"

An investment committee is a small group of experienced people who set the rules and make the key decisions about what investments to buy, hold, or sell for a fund, pension, or portfolio. Think of them as the steering team that balances goals, potential returns and risk—their choices shape how much money investors are likely to gain or lose and provide consistent oversight so decisions aren’t made impulsively.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 8)

KalVista Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

483497103

(CUSIP Number)

Jennifer Martin
1700 Seventh Ave, Suite 1120,
Seattle, WA, 98101
(206) 451-8040

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

05/19/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 483497103

1

Name of reporting person

Frazier Life Sciences Public Fund, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,249,165.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,249,165.00

11

Aggregate amount beneficially owned by each reporting person

1,249,165.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.3 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 483497103

1

Name of reporting person

FHMLSP, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,249,165.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,249,165.00

11

Aggregate amount beneficially owned by each reporting person

1,249,165.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.3 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 483497103

1

Name of reporting person

FHMLSP, L.L.C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,249,165.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,249,165.00

11

Aggregate amount beneficially owned by each reporting person

1,249,165.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.3 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 483497103

1

Name of reporting person

Frazier Life Sciences X, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 427,983.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 427,983.00

11

Aggregate amount beneficially owned by each reporting person

427,983.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.8 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 483497103

1

Name of reporting person

FHMLS X, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 427,983.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 427,983.00

11

Aggregate amount beneficially owned by each reporting person

427,983.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.8 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 483497103

1

Name of reporting person

FHMLS X, L.L.C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 427,983.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 427,983.00

11

Aggregate amount beneficially owned by each reporting person

427,983.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.8 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 483497103

1

Name of reporting person

Frazier Life Sciences XI, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 145,592.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 145,592.00

11

Aggregate amount beneficially owned by each reporting person

145,592.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.3 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 483497103

1

Name of reporting person

FHMLS XI, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 145,592.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 145,592.00

11

Aggregate amount beneficially owned by each reporting person

145,592.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.3 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 483497103

1

Name of reporting person

FHMLS XI, L.L.C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 145,592.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 145,592.00

11

Aggregate amount beneficially owned by each reporting person

145,592.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.8 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 483497103

1

Name of reporting person

Frazier Life Sciences XII, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 6,563.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 6,563.00

11

Aggregate amount beneficially owned by each reporting person

6,563.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 483497103

1

Name of reporting person

FHMLS XII, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 6,563.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 6,563.00

11

Aggregate amount beneficially owned by each reporting person

6,563.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 483497103

1

Name of reporting person

FHMLS XII, L.L.C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 6,563.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 6,563.00

11

Aggregate amount beneficially owned by each reporting person

6,563.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 483497103

1

Name of reporting person

James N. Topper

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 427,983.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 427,983.00

11

Aggregate amount beneficially owned by each reporting person

427,983.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.8 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

The shares listed in rows 8, 10 and 11 represent shares of Common Stock held directly by Frazier Life Sciences X, L.P. The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 483497103

1

Name of reporting person

Patrick J. Heron

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 427,983.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 427,983.00

11

Aggregate amount beneficially owned by each reporting person

427,983.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.8 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

The shares listed in rows 8, 10 and 11 represent shares of Common Stock held directly by Frazier Life Sciences X, L.P. The percentage listed in row 13 is calculated based on 53,240,888 shares of the Issuer's Common Stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, $0.001 par value per share
(b)	Name of Issuer: KalVista Pharmaceuticals, Inc.
(c)	Address of Issuer's Principal Executive Offices: 200 Crossing Boulevard, Framingham, MASSACHUSETTS , 01702.
Item 1 Comment: This Amendment No. 8 ("Amendment No. 8") to Schedule 13D amends the statement on Schedule 13D filed on December 30, 2021 (the "Original Schedule 13D") as amended on January 26, 2022, December 30, 2022, December 14, 2023, February 22, 2024, November 7, 2024, August 20, 2025 and November 4, 2025 (the "Prior Amendments", and together with the Original Schedule 13D and this Amendment No. 8, the "Schedule 13D"). Except as otherwise specified in Amendment No. 8, all items in the Original Schedule 13D, as amended by the Prior Amendments, are unchanged. All capitalized terms used in this Amendment No. 8 and not otherwise defined herein have the meanings ascribed to such terms in the Original Schedule 13D, as amended by the Prior Amendments.
Item 2.	Identity and Background
(a)	Item 2(a) is hereby amended and restated in its entirety to read as follows: The entities and persons filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences Public Fund, L.P. ("FLSPF") FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences X, L.P. ("FLS X") FHMLS X, L.P. FHMLS X, L.L.C. Frazier Life Sciences XI, L.P. ("FLS XI") FHMLS XI, L.P. FHMLS XI, L.L.C. Frazier Life Sciences XII, L.P. ("FLS XII") FHMLS XII, L.P. FHMLS XII, L.L.C. James N. Topper ("Topper") Patrick J. Heron ("Heron" and together with Topper, the "Members")
(b)	Item 2(b) is hereby amended and restated in its entirety to read as follows: The address of the principal place of business for each of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 1001 Page Mill Rd, Building 4, Suite 200B Palo Alto, CA 94304
(c)	Item 2(c) is hereby amended and restated in its entirety to read as follows: FLSPF is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLSP, L.P. is to serve as general partner of FLSPF. The sole business of FHMLSP, L.L.C. is to serve as general partner of FHMLSP, L.P. FLS X is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLS X, L.P. is to serve as general partner of FLS IX. The sole business of FHMLS X, L.L.C. is to serve as general partner of FHMLS X, L.P. FLS XI is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLS XI, L.P. is to serve as general partner of FLS XI. The sole business of FHMLS XI, L.L.C. is to serve as general partner of FHMLS XI, L.P. FLS XII is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLS XII, L.P. is to serve as general partner of FLS XII. The sole business of FHMLS XII, L.L.C. is to serve as general partner of FHMLS XII, L.P. The principal business of the Members is to manage FLSPF, FHMLSP, L.P., FHMLSP, L.L.C., FLS X, FHMLS X, L.P., FHMLS X, L.L.C., FLS XI, FHMLS XI, L.P., FHMLS XI, L.L.C., FLS XII, FHMLS XII, L.P., FHMLS XII, L.L.C. and a number of affiliated partnerships with similar businesses.
(f)	Item 2(f) is hereby amended and restated in its entirety to read as follows: Entities: FLSPF - Delaware, U.S.A. FHMLSP, L.P. - Delaware, U.S.A. FHMLSP, L.L.C. - Delaware, U.S.A. FLS X - Delaware, U.S.A. FHMLS X, L.P. - Delaware, U.S.A. FHMLS X, L.L.C. - Delaware, U.S.A. FLS XI - Delaware, U.S.A. FHMLS XI, L.P. - Delaware, U.S.A. FHMLS XI, L.L.C. - Delaware, U.S.A. FLS XII - Delaware, U.S.A. FHMLS XII, L.P. - Delaware, U.S.A. FHMLS XII, L.L.C. - Delaware, U.S.A. Individuals: Topper - United States Citizen Heron - United States Citizen
Item 3.	Source and Amount of Funds or Other Consideration
	Item 3 of the Schedule 13D is hereby amended to incorporate Item 5(c) hereof and to replace the last paragraph with the following: The working capital of FLSPF, FLS X, FLS XI and FLS XII was the source of the funds for the purchase of the FLSPF Shares, the FLS X Shares, the FLS XI Shares and the FLS XII Shares. No part of the purchase price of the FLSPF Shares, the FLS X Shares, the FLS XI Shares or the FLS XII Shares was represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the FLSPF Shares, the FLS X Shares, the FLS XI Shares or the FLS XII Shares.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5(a) is hereby amended and restated in its entirety to read as follows: The information contained in Rows 7, 8, 9, 10, 11, and 13 of each Reporting Person's cover page to this Schedule 13D (including the footnotes thereto) is incorporated by reference into this Item 5. FLSPF directly holds 1,249,165 shares of the Issuer's Common Stock (the "FLSPF Shares"). FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF. FLS X directly holds 427,983 shares of the Issuer's Common Stock (the "FLS X Shares"). FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the FLS X Shares. FLS XI directly holds 145,592 shares of this Issuer's Common Stock (the "FLS XI Shares"). FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI. FLS XII directly holds 6,563 shares of this Issuer's Common Stock (the "FLS XII Shares"). FHMLS XII, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII. Except as specifically stated herein, the filing of this Schedule 13D shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Schedule 13D or a member of a "group" with any other person.
(c)	Except as set forth on Exhibit 10.1 of this Schedule 13D, none of the Reporting Persons has effected any transactions relating to the Ordinary Shares during the past 60 days.
(e)	May 19, 2026
Item 7.	Material to be Filed as Exhibits.
	Exhibit 10.1 Transactions Relating to the Common Stock of the Issuer During the Past Sixty (60) Days Exhibit 99.1 Joint Filing Agreement

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Frazier Life Sciences Public Fund, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:	05/21/2026

FHMLSP, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:	05/21/2026

FHMLSP, L.L.C.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLSP, L.L.C.
Date:	05/21/2026

Frazier Life Sciences X, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
Date:	05/21/2026

FHMLS X, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
Date:	05/21/2026

FHMLS X, L.L.C.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS X, L.L.C.
Date:	05/21/2026

Frazier Life Sciences XI, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:	05/21/2026

FHMLS XI, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:	05/21/2026

FHMLS XI, L.L.C.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS XI, L.L.C.
Date:	05/21/2026

Frazier Life Sciences XII, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.
Date:	05/21/2026

FHMLS XII, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.
Date:	05/21/2026

FHMLS XII, L.L.C.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS XII, L.L.C.
Date:	05/21/2026

James N. Topper

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, Attorney-in-Fact for Patrick J. Heron, pursuant to Power of Attorney
Date:	05/21/2026

Patrick J. Heron

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, Attorney-in-Fact for Patrick J. Heron, pursuant to Power of Attorney
Date:	05/21/2026

FAQ

What stake do Frazier Life Sciences funds report in KalVista Pharmaceuticals (KALV)?

Frazier Life Sciences Public Fund, L.P. reports 1,249,165 KalVista shares, or 2.3% of outstanding stock. Additional Frazier funds hold 427,983, 145,592, and 6,563 shares respectively, reflecting several smaller positions across related venture capital vehicles.

Which Frazier entities are listed as reporting persons in this KalVista Schedule 13D/A?

Reporting persons include multiple Frazier Life Sciences funds and their general partners, plus individuals James N. Topper and Patrick J. Heron. The entities span FLSPF, FLS X, FLS XI, FLS XII and related FHMLSP and FHMLS partnerships and LLCs, all organized in Delaware.

How is the ownership percentage in KalVista (KALV) calculated in this filing?

Each percentage is based on 53,240,888 KalVista common shares outstanding as of May 7, 2026. This share count comes from KalVista’s Form 10-Q filed on May 14, 2026 and is used consistently for all reporting persons’ ownership calculations.

What role do James N. Topper and Patrick J. Heron play in the KalVista holdings?

James N. Topper and Patrick J. Heron are members of FHMLS X, L.L.C. and share voting and investment power over 427,983 KalVista shares held by Frazier Life Sciences X, L.P. For other Frazier funds, investment committees manage holdings without attributing beneficial ownership to individual members.

What does the KalVista Pharmaceuticals Schedule 13D Amendment No. 8 change?

Amendment No. 8 updates the list of reporting persons, their business descriptions, jurisdictions, and detailed share ownership. It restates key identity and ownership sections, while incorporating that the Frazier funds used working capital to purchase their KalVista positions.

How were the Frazier funds’ KalVista (KALV) shares financed according to the filing?

The filing states that working capital of Frazier Life Sciences Public Fund, X, XI and XII financed their KalVista share purchases. It specifies that no portion of the purchase price was borrowed or otherwise obtained for acquiring, holding, trading, or voting these shares.